# OnCo record platinum-resistant-ovarian-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "platinum-resistant-ovarian-cancer" ;
  schema:name "Platinum-resistant ovarian cancer"@en ;
  schema:alternateName "Platinum-resistant recurrent ovarian cancer"@en, "Platinum-refractory ovarian cancer"@en, "Platinum-free interval under six months"@en, "PROC"@en ;
  schema:description "Platinum-resistant ovarian cancer grows back within six months of platinum chemotherapy, or during it, and used to be treated with single chemotherapy drugs that shrink a tumour one time in ten. The antibody-drug conjugate mirvetuximab soravtansine, the cortisol-blocking drug relacorilant and pembrolizumab in PD-L1-positive tumours have each extended survival in phase 3 trials since 2023."@en ;
  schema:url <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/raludotatug-deruxtecan/>, <https://onco.cc/trials/rejoice-ovarian01/>, <https://onco.cc/drugs/rinatabart-sesutecan/>, <https://onco.cc/trials/rainfol-01/>, <https://onco.cc/drugs/luveltamab-tazevibulin/>, <https://onco.cc/drugs/relacorilant/>, <https://onco.cc/ideas/idea-fra-adc-sequencing-ovarian/> ;
  onco:standardOfCare <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/trials/mirasol/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/keynote-b96/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/drugs/relacorilant/>, <https://onco.cc/trials/rosella/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/raludotatug-deruxtecan/>, <https://onco.cc/trials/rejoice-ovarian01/>, <https://onco.cc/drugs/rinatabart-sesutecan/>, <https://onco.cc/trials/rainfol-01/>, <https://onco.cc/drugs/luveltamab-tazevibulin/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/cancers/ovarian/> .